The comparison of therapeutic effects of foscarnet in the treatment of active and inactive cytomegalovirus infection after renal transplantation
- VernacularTitle:膦甲酸钠用于巨细胞病毒感染静止期与活动期的效果对比
- Author:
Jizhong REN
;
Zhilian MIN
;
Youhua ZHU
- Publication Type:Journal Article
- Keywords:
Cytomegaloviruses;
Infection;
Drug therapy;
Antiviral agents
- From:
Chinese Journal of Organ Transplantation
1999;20(1):37-39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the therapeutic effects and side effects of foscarnet in the treatment of active(IgG+,IgM+)and inactive(IgC+,IgM-)cytomegalovirus(CMV)infection after cadaver renal transplantation.Methods Forty-one cases of active cytomegalovirus infection and 22 of inactive cytomegalovirus were selected to receive foscarnet treatment.Besides,10 cases of inactive cytomegalovirus infection served as control group without receiving foscarnet.The usage of foscarnet was 40 mg/kg,iv.,2 ～3 weeks in the active stage,50 mg/kg,iv.,3～4 weeks in the inactive stage.Results Clinical symptoms of patients in the active stage were controlled,and serologic CMV IgG turned negative.Moreover,no positive infection was found after 3-month follow-up for those who received foscarnet.At the same time, 3 patients in the control group turned into active infection. Only one receiving foscarnet appeared urine volume cutting down temporarily,and the renal function had a reversible change;2 patients had skin red reaction.Conclusion Foscarnet could control CMV active infection quickly,markedly and firmly.and no recurrence was found during a 3-month follow-up.Foscarnet may protect the inactive patients from turning positive.And foscarnet had no obvious damage to the renal graft function and didn't interfere with the metabolism of blood calcium and cyclosporine A.Foscarnet is a safe and effective drug to treat CMV infection.
